entertainment -WSS

entertainment

author：hotspot 2025-10-01 04:13:12 - browse：13725

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Ascension's ugly legal battle over care for poor patients in Texas

hotspot

WSS

CRISPR base editing slashes cholesterol levels in monkeys

Flu, Covid vaccination rates decline, new survey data show

New oral drug delivery patch is modeled after octopus tentacles

Hospital chaplains balance Covid safety with patients’ spiritual needs

The biotech scorecard for Q4: 16 stock

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

focus

entertainment

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Congress extends some pandemic preparedness programs

Cancer drug shortages should be causing more outrage

The biotech scorecard for Q4: 16 stock

Novavax promises a turnaround & Lilly roils the obesity market

Profiling embryos to choose those with higher IQs is almost a reality

Medicare details structure of new drug price negotiation program

Arena BioWorks launches in Cambridge to speed drug discovery

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

focus

The stability of $0 premiums in Medicare Advantage

Boston Scientific acquires urology company Axonics for $3.7 billion

6 solutions to address cancer drug shortages and others

Some top drug companies are starting to take action on climate

Male doctors called my cancer incurable. A female doctor showed it wasn't

2023 Nobel Prize in Medicine goes to Karikó and Weissman

focus

hotspot

Wikipedia

hotspot